Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 16/20 | 0.39 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14067053 | 0.87 | CXCR4 (0.39) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL4882916 | 0.84 | CXCR4 (0.57) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL4905253 | 0.80 | HTR6 (0.48) | CXCR4KCNH2 | |
| SCHEMBL4894677 | 0.80 | HTR6 (0.46) | CXCR4CHRM2CYP2D6KCNH2 | |
| SCHEMBL4879547 | 0.75 | CXCR4 (0.57) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL4899934 | 0.74 | PARP1 (0.38) | — | |
| SCHEMBL14098339 | 0.73 | CXCR4 (0.33) | CXCR4KCNH2 | |
| SCHEMBL14067054 | 0.70 | CXCR4 (0.41) | CXCR4CHRM2CYP2D6KCNH2 | |
| SCHEMBL14067034 | 0.70 | CXCR4 (0.43) | CXCR4KCNH2 | |
| SCHEMBL4885418 | 0.69 | CXCR4 (0.55) | CXCR4CHRM2CYP2D6DRD2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214562-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | claimed |
| US-20080214562-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214562-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | CXCR4 2/4885KCNMA1 4701/4885LMNA 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.